EyeGate Pharmaceuticals

EyeGate Pharmaceuticals FCF Conversion

The FCF Conversion Rate (FCF/EBITDA) of EyeGate Pharmaceuticals (EYEG) as of Nov 2, 2026 is 90.73 %. In the previous year, FCF Conversion Rate (FCF/EBITDA) was 114.79 % — a change of -20.96% (lower).

FCF Conversion

90.73 %

YoY

-20.96%

Last updated:

FCF Conversion Rate (FCF/EBITDA) of EyeGate Pharmaceuticals is 2020 90.73 % . FCF Conversion Rate (FCF/EBITDA) of EyeGate Pharmaceuticals was 2019 114.79 % . It decreases by -20.96% lower compared to the previous year.

The EyeGate Pharmaceuticals FCF Conversion history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

FCF Conversion
Date
FCF Conversion
Jan 1, 2014
53.67 USD
Jan 1, 2015
53.16 USD
Jan 1, 2016
63.12 USD
Jan 1, 2017
49.24 USD
Jan 1, 2018
102.78 USD
Jan 1, 2019
114.79 USD
Jan 1, 2020
90.73 USD
The EyeGate Pharmaceuticals FCF Conversion history
YEARFCF ConversionYoY
90.73 %-20.96%
114.79 %+11.69%
102.78 %+108.71%
49.24 %-21.98%
63.12 %+18.74%
53.16 %-0.96%
53.67 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

EyeGate Pharmaceuticals Stock analysis

What does EyeGate Pharmaceuticals do? EyeGate Pharmaceuticals Inc. is a US pharmaceutical company specializing in the development of ophthalmology products. It was founded in 1998 and is headquartered in Waltham, Massachusetts. The company aims to meet the need for safe and effective therapies for the treatment of eye diseases. Its business model focuses on the development and commercialization of products that enable faster and more effective treatment of eye diseases. The company has two main divisions. The first division includes iontophoretic drug delivery technologies used for the treatment of eye diseases. Iontophoresis is a process in which electric currents are used to transport medications through the skin and into the eyes. EyeGate Pharmaceuticals has developed the EyeGate® II Delivery System technology, which allows for non-invasive, painless, and safe administration of medications into the eye. The EyeGate II Delivery System can be used for the treatment of inflammation, pain, and infections in the eye area. The second division is the development of drugs used for the treatment of eye diseases. EyeGate Pharmaceuticals has several clinical programs in development, including EGP-437, a steroid-free corticosteroid used for the treatment of inflammation of the anterior eye segment. EGP-437 is currently being tested in two clinical trials to demonstrate its efficacy and safety in the treatment of pain and inflammation in the eye. In addition, the company has developed the drug EGP-259 for the treatment of dry eye. EyeGate Pharmaceuticals has previously entered into several partnerships with other companies to further develop and commercialize its technology platform. In 2019, the company entered into a partnership with Valeant Pharmaceuticals International, Inc. to advance the marketing of EGP-437 in the United States. EyeGate Pharmaceuticals aims to continue growing and expanding its presence in the field of ophthalmology in the coming years. The company is working on the development of new products and technologies that enable it to respond to the changing needs and challenges in ophthalmology. Overall, EyeGate Pharmaceuticals is committed to developing and marketing innovative and effective technologies and drugs for the treatment of eye diseases. The company is well positioned to grow in a rapidly evolving market and make a significant contribution to improving the health and quality of life of millions of people worldwide. EyeGate Pharmaceuticals is one of the most popular companies on Eulerpool.

Frequently Asked Questions about EyeGate Pharmaceuticals stock

FCF Conversion Rate (FCF/EBITDA) of EyeGate Pharmaceuticals is 90.73 % in 2020.

FCF Conversion Rate (FCF/EBITDA) of EyeGate Pharmaceuticals changed from 114.79 % to 90.73 %, representing a -20.96% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of FCF Conversion Rate (FCF/EBITDA) EyeGate Pharmaceuticals since 2006 – with annual values, charts, and detailed analysis.

FCF conversion measures how effectively EBITDA converts to free cash flow. Higher conversion indicates efficient capital allocation and low maintenance costs.

A 'good' varies by industry and company stage. On Eulerpool, you can compare FCF Conversion Rate (FCF/EBITDA)'s EyeGate Pharmaceuticals with sector peers and the industry average to assess whether it is attractive.

To evaluate FCF Conversion Rate (FCF/EBITDA)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for FCF Conversion Rate (FCF/EBITDA).

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Cash Flow — EyeGate Pharmaceuticals

All Key Metrics — EyeGate Pharmaceuticals